IceCure Medical (NASDAQ:ICCM) Releases Quarterly Earnings Results, Misses Estimates By $0.01 EPS

IceCure Medical (NASDAQ:ICCM) posted its earnings results on Thursday. The company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01), Zacks reports. The company had revenue of $1.07 million for the quarter, compared to analyst estimates of $1.07 million. IceCure Medical had a negative return on equity of 124.44% and a negative net margin of 376.85%.

IceCure Medical Stock Performance

Shares of ICCM traded down $0.02 during mid-day trading on Friday, hitting $1.08. 51,492 shares of the company’s stock were exchanged, compared to its average volume of 519,416. The company has a quick ratio of 2.27, a current ratio of 2.67 and a debt-to-equity ratio of 0.02. IceCure Medical has a 52 week low of $0.48 and a 52 week high of $1.66. The stock’s 50-day simple moving average is $1.32 and its 200-day simple moving average is $0.98. The firm has a market cap of $60.16 million, a price-to-earnings ratio of -3.72 and a beta of 0.37.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and set a $2.50 price target on shares of IceCure Medical in a report on Friday.

IceCure Medical Company Profile

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.